Ig demand remains strong. CSL guides to double-digit second-half sales growth on recent market share gains and excess industry supply resetting. We expect Ig sales growth to slow to 7% at midcycle on ...
CanSino Biologics Inc. ("CanSinoBIO"; SSE: 688185, HKEX: 06185) has been invited to share the practices of innovative vaccine ...
Q2 2026 Earnings Call February 10, 2026 6:00 PM ESTCompany ParticipantsMark DehringGordon NaylorKen Lim - Chief Financial ...
The Australian sharemarket concluded Tuesday's session nearly unchanged, with a late downturn in CSL contributing to the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results